Clinical trials: Intravenous
Autism
Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism
Allogeneic (not from the subject) human umbilical cord tissue-derived stem cells administered intravenously (IV) in a series of 4 infusions every 3 months over the course of one year is safe and will induce a therapeutic effect…
- Trial name
- NCT02192749
- Testing
- Umbilical cord mesenchymal stem cells
- Where
- Panama
- Volunteers
- 20 people
- Sponsor
- Translational Biosciences
Chronic Obstructive Pulmonary Disease
Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients
In MediciNova's clinical development plan for MN-221, it was recognized that treatment of COPD exacerbations may necessitate more than one single i.v.
- Trial name
- NCT01551316
- Testing
- MN-221
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- MediciNova
Healthy
Pharmacokinetics and Pharmacodynamics of BIWH 3 in Healthy Duffy Positive vs. Duffy Negative Male Volunteers
Study to compare the pharmacokinetic and pharmacodynamic effects of escalating dosages of recombinant human pyro-Glu MCP-1 (BIWH 3) in Duffy positive vs.
- Trial name
- NCT02249117
- Testing
- BIWH 3
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Post-Acute COVID-19 Syndrome, Cognitive Impairment
Safety, Efficacy, and Dosing of VIX001 in Patients With Neurological Symptoms of Post Acute COVID-19 Syndrome (PACS).
The study, identified as VIX001-PACS-01, is a Phase 1, open-label, dose-escalation trial evaluating the safety, tolerability, preliminary efficacy, and dose effect of VIX001, an amniotic fluid product, in patients with Post-Acute…
- Conditions
- Post-Acute COVID-19 Syndrome, Cognitive Impairment, Neurological Complication
- Trial name
- NCT05947617
- Testing
- VIX001
- Volunteers
- 9 people
- Sponsor
- Neobiosis, LLC
Post Menopausal Osteoporosis
DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
This study will assess the efficacy and safety of intravenous administration of Bonviva regimens in women with post-menopausal osteoporosis, compared to oral daily administration.
- Trial name
- NCT00048074
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 64 sites in United States, Australia and 14 more
- Volunteers
- 1,395 people
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers
A Study to Assess ASP2713 in Healthy Subjects
The purpose of this study is to evaluate safety and tolerability of ASP2713 in healthy participants. The study will also evaluate the pharmacokinetics and pharmacodynamics of ASP2713.
- Trial name
- NCT04017208
- Testing
- ASP2713
- Volunteers
- healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Episodic Migraine
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
- Trial name
- PROSPECT-1 (NCT05897320)
- Testing
- Eptinezumab
- Where
- 60 sites in United States, Argentina and 9 more
- Volunteers
- 315 people
- Sponsor
- H. Lundbeck A/S
Alzheimer Disease
A Safety and Tolerability Study of GB301
The primary objective of this study is to evaluate the safety and tolerability of multiple intravenous (IV) infusions at a single dose strength of GB301 in subjects with mild to moderate AD.
- Trial name
- NCT03865017
- Testing
- Regulatory T cells, Saline
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- VTBIO Co. LTD
Raynaud Phenomenon Secondary to Systemic Sclerosis
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)
This is a Phase 2, multicenter, double-blind, randomized, placebo-controlled study to evaluate the effect of iloprost on the symptomatic relief of Raynaud's Phenomenon attacks in subjects with symptomatic Raynaud's Phenomenon…
- Trial name
- NCT03867097
- Testing
- Iloprost Injection, for intravenous use
- Where
- 16 sites in United States
- Volunteers
- 34 people
- Sponsor
- Civi Biopharma, Inc.
Hypercholesterolemia, Dyslipidemia
Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia
The primary objective of this study is to evaluate the safety and tolerability of repeated doses of RN316 in eligible healthy volunteers.
- Trial name
- NCT01163838
- Testing
- 1 mg/kg every 2 weeks, 2 mg/kg every 4 weeks, 4 mg/kg every 4 weeks
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Alpha1-Antitrypsin Deficiency
Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)
This is a multi-center, open-label study to evaluate the long-term safety of weekly intravenous (IV) infusions of 60 mg/kg alpha1-PI (human), modified process (Alpha-1 MP) in adult participants with Alpha1 Antitrypsin Deficiency…
- Trial name
- NCT02870348
- Testing
- Alpha-1 MP
- Where
- 3 sites in Japan
- Volunteers
- 4 people
- Sponsor
- Grifols Therapeutics LLC
Tumors, Neoplasms
Phase I Study of LB-100 With Docetaxel in Solid Tumors
The purpose of this study is to test the safety of an investigational drug called LB-100 for Injection for treatment of solid tumors, when given with or without docetaxel.
- Conditions
- Tumors, Neoplasms, Cancer
- Trial name
- NCT01837667
- Testing
- LB-100 for Injection, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Lixte Biotechnology Holdings, Inc.
Spinal Muscular Atrophy Type I
Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies
This is a Phase 3, open-label, single-arm, single-dose, trial of onasemnogene abeparvovec-xioi (gene replacement therapy) in participants with spinal muscular atrophy (SMA) Type 1 and who are genetically defined by a biallelic…
- Trial name
- NCT03837184
- Testing
- Onasemnogene Abeparvovec-xioi
- Where
- 4 sites in Japan, South Korea and 1 more
- Volunteers
- 2 people
- Sponsor
- Novartis Gene Therapies
Lung Cancer
DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have previously…
- Trial name
- NCT00005091
- Testing
- exatecan mesylate
- Where
- 6 sites in Finland, Germany and 3 more
- Sponsor
- Daiichi Pharmaceuticals
Neoplasms
A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors
This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors.
- Trial name
- KOURAGE (NCT03967093)
- Testing
- BXQ-350
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Healthy Volunteers
A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People
This study is testing a new medicine, in healthy adults to assess its safety and understand how it behaves in the body. The purpose of this study is to evaluate the safety, tolerability, and how the body responds to a single dose…
- Trial name
- NCT07829406
- Testing
- NNC0642-1895
- Where
- United States
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Fabry Disease
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
This is the first human treatment with PRX-102, an enzyme being developed as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (alpha galactosidase deficiency).
- Trial name
- NCT01678898
- Testing
- PRX-102
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 18 people
- Sponsor
- Protalix
Nausea and Vomiting, Postoperative, Postoperative Nausea and Vomiting
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
- Trial name
- NCT00334152
- Testing
- casopitant
- Where
- 70 sites in United States, Belgium and 9 more
- Volunteers
- 515 people
- Sponsor
- GlaxoSmithKline
Bacterial Pneumonia
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
Study 0015 (NCT00107952) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
- Trial name
- ATTAIN1 (NCT00107952)
- Testing
- Telavancin, Vancomycin
- Where
- United States
- Volunteers
- 761 people
- Sponsor
- Cumberland Pharmaceuticals
Acute Pain
A Single Dose Study of SHR0410 in Healthy Male Participants
This is a randomized, double-blind, placebo-controlled, single ascending-dose study to investigate the effect of a single intravenous (IV) dose of SHR0410 at 6 dose levels (0.5 μg/kg, 1 μg/kg, 2 μg/kg, 5 μg/kg, 10 μg/kg and 20…
- Trial name
- NCT03493191
- Testing
- 0.5μg/kg SHR0410, 1μg/kg SHR0410, 2μg/kg SHR0410
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Atridia Pty Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.